Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Gynecol Oncol ; 101(3): 545-7, 2006 Jun.
Article in English | MEDLINE | ID: mdl-16487996

ABSTRACT

BACKGROUND: High-grade endometrial stromal sarcoma (HGES) is an aggressive disease with dismal prognosis. Surgery is the standard treatment, and radiotherapy seems to reduce local relapse. No other treatment has proved to be useful in the case of non-resectable diseases. CASE: A 41-year-old woman suffering HGES, with positive staining for CD117 (c-kit) and large abdominal and retroperitoneal mass progressing after chemotherapy, was treated with Imatinib Mesylate. After 3 months, objective response was documented and radical surgery performed. Two years after surgical intervention, she is currently free of the disease. CONCLUSION: The response seen with Imatinib should be further investigated in a larger number of cases.


Subject(s)
Antineoplastic Agents/therapeutic use , Piperazines/therapeutic use , Proto-Oncogene Proteins c-kit/biosynthesis , Pyrimidines/therapeutic use , Sarcoma, Endometrial Stromal/drug therapy , Sarcoma, Endometrial Stromal/metabolism , Vaginal Neoplasms/drug therapy , Vaginal Neoplasms/metabolism , Adult , Benzamides , Female , Humans , Imatinib Mesylate , Proto-Oncogene Proteins c-kit/genetics , Sarcoma, Endometrial Stromal/genetics , Vaginal Neoplasms/genetics
SELECTION OF CITATIONS
SEARCH DETAIL
...